<DOC>
	<DOC>NCT01653639</DOC>
	<brief_summary>This is a single dose, open-label, randomized, crossover study in subjects with severe Hemophilia A to compare the bioavailability of 2 different strengths of Kogenate FS (BAY 14-2222).</brief_summary>
	<brief_title>Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Males, age 18 to 65 years Subjects with Severe hemophilia A with a documented plasma FVIII level of &lt;1% &gt;/= 150 ED (exposure days) with FVIII concentrates(s) as supported by medical records Evidence of current or past inhibitor antibody History of any congenital or acquired coagulation disorders other than hemophilia A Platelet count &lt;75,000/mm3 Abnormal renal function (serum creatinine &gt;2 times the upper limit of the normal range) Active liver disease verified by medical history or persistently elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;5x the upper limit of normal or severe liver disease as evidenced by, but not limited to any of the following: International Normalized Ratio (INR) &gt;1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>BAY14-2222</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>